How to buy Control Bionics shares
Own Control Bionics shares in just a few minutes.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Control Bionics Limited is a medical devices business based in Australia. Control Bionics shares (CBL) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Control Bionics has a trailing 12-month revenue of around $3.2 million.
How to buy shares in Control Bionics
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Control Bionics. Find the share by name or ticker symbol: CBL. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Control Bionics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Control Bionics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Control Bionics share priceUse our graph to track the performance of CBL stocks over time.
Control Bionics shares at a glance
|52-week range||$0.61 - $1.24|
|50-day moving average||$0.7388|
|200-day moving average||$0.8447|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Compare share trading platforms
Is it a good time to buy Control Bionics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Control Bionics financials
|Revenue TTM||$3.2 million|
|Gross profit TTM||$2.5 million|
|Return on assets TTM||-11.69%|
|Return on equity TTM||-18.66%|
|Market capitalisation||$55.1 million|
TTM: trailing 12 months
Control Bionics share dividends
We're not expecting Control Bionics to pay a dividend over the next 12 months.
Control Bionics overview
Control Bionics Limited designs, manufactures, and sells wireless wearable electromyography based augmentative and alternative communication technologies that allow users to operate and communicate through a computer using their thoughts and neuroelectric signals. It offers Eye Control Duo, an integrated eye tracking device for those living with paralysis and loss of speech; NeuroNode Trilogy, a solution for those living with paralysis and loss of speech; and Control Bionics Complete Communication System, an out of the box solution for those living with paralysis and loss of speech. The company also provides support and warranty services. The company's products are used by people suffering from diseases, such as motor neuron diseases, amyotrophic lateral sclerosis, cerebral palsy, multiple sclerosis, and spinal cord injuries. It operates in Australia, the United States, Japan, and internationally. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Surrey Hills, Australia.
Frequently asked questions
Ask an Expert